EBITDA for Stryker (SYK)
According to Stryker's latest reported financial statements, the company's current EBITDA (TTM) is $5.58B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
SYK
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$5.58B
YoY change
+27.9%
5Y CAGR
+15.4%
Peak year (2025)
$6.31B
Cumulative EBITDA
$65.95B
EBITDA history chart for Stryker (SYK) from 1985 to 2025
EBITDA history table for Stryker (SYK) from 1985 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $6.31B | +27.9% | ||
| 2024 | $4.94B | -2.4% | ||
| 2023 | $5.06B | +25.9% | ||
| 2022 | $4.02B | +11.4% | ||
| 2021 | $3.61B | +17.1% | ||
| 2020 | $3.08B | -15.1% | ||
| 2019 | $3.63B | +8.5% | ||
| 2018 | $3.34B | +13.2% | ||
| 2017 | $2.95B | +9.5% | ||
| 2016 | $2.69B | +20.3% | ||
| 2015 | $2.24B | +35.7% | ||
| 2014 | $1.65B | +2.3% | ||
| 2013 | $1.61B | -21.2% | ||
| 2012 | $2.05B | -9.4% | ||
| 2011 | $2.26B | +2.0% | ||
| 2010 | $2.22B | +9.6% | ||
| 2009 | $2.02B | +1.3% | ||
| 2008 | $2.00B | +13.6% | ||
| 2007 | $1.76B | +21.7% | ||
| 2006 | $1.45B | +15.4% | ||
| 2005 | $1.25B | +28.5% | ||
| 2004 | $974.70M | +8.2% | ||
| 2003 | $901.00M | +20.0% | ||
| 2002 | $750.80M | +16.5% | ||
| 2001 | $644.60M | +7.6% | ||
| 2000 | $599.00M | +13.6% | ||
| 1999 | $527.50M | +117.9% | ||
| 1998 | $242.10M | +3.7% | ||
| 1997 | $233.50M | +38.2% | ||
| 1996 | $168.90M | -9.2% | ||
| 1995 | $186.00M | +31.5% | ||
| 1994 | $141.40M | +30.8% | ||
| 1993 | $108.10M | +27.0% | ||
| 1992 | $85.10M | +34.4% | ||
| 1991 | $63.30M | +47.9% | ||
| 1990 | $42.80M | +12.6% | ||
| 1989 | $38.00M | +17.3% | ||
| 1988 | $32.40M | +23.7% | ||
| 1987 | $26.20M | +18.6% | ||
| 1986 | $22.10M | +25.6% | ||
| 1985 | $17.60M | — |
EBITDA values are taken from Stryker's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Stryker (SYK) most recent annual EBITDA stands at $6.31B (2025) – grew 27.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Stryker EBITDA compounded at +15.4% per year, with the latest reading among the more recent periods of the dataset.
$6.31B stands as the all-time-high annual EBITDA, posted in 2025, against a low of $17.60M during 1985.
Stryker (SYK) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $24.21B.
Stryker EBITDA by Year
Stryker EBITDA 2025: $6.31B
Stryker EBITDA in 2025 was $6.31B, grew 27.9% from 2024. This figure represents the highest annual value in the available history.
Stryker EBITDA 2024: $4.94B
Stryker EBITDA in 2024 was $4.94B, edged down 2.4% below 2023.
Stryker EBITDA 2023: $5.06B
Stryker EBITDA in 2023 was $5.06B, grew 25.9% from 2022.
Stryker EBITDA 2022: $4.02B
Stryker EBITDA in 2022 was $4.02B, grew 11.4% from 2021.
Stryker EBITDA 2021: $3.61B
Stryker EBITDA in 2021 was $3.61B.
See more financial history for Stryker (SYK).
Sector peers — EBITDA
Companies in the same sector as Stryker, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Stryker's EBITDA?
- Latest reported EBITDA for Stryker (SYK) is $5.58B (period ending December 31, 2025).
How has Stryker EBITDA changed year-over-year?
- Stryker (SYK) EBITDA changed +27.9% year-over-year on the latest annual filing.
What is the long-term growth rate of Stryker EBITDA?
- Stryker (SYK) EBITDA compound annual growth rate is +15.4% over the most recent 5 years available.
When did Stryker EBITDA hit its highest annual value?
- Stryker EBITDA reached its highest annual value of $6.31B in 2025.
What was Stryker EBITDA in 2024?
- Stryker (SYK) EBITDA in 2024 was $4.94B.
What was Stryker EBITDA in 2025?
- Stryker (SYK) EBITDA in 2025 was $6.31B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
SYK Overview
Company profile, financial tools, and key metrics
SYK Revenue Counter
Earns $796.42 every second. See per minute, hour, and day.
SYK Earnings Counter
Earns $102.93 per second net profit. See per minute, hour, and day.
SYK Economic Scale
Exceeds Guinea's GDP. Compare with world economies.
SYK What If Invested
What if you had invested $1,000? See historical returns from any date.
SYK How It Makes Money
Discover visual breakdown of $25.12B in revenue — where it comes from and where it goes.
SYK Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
SYK Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
SYK Daily Price Character
Balanced · 47.3% historical win rate (green days). Streaks & record days.
SYK Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
SYK Stock Split History
9 splits on record. Dates, ratios, and cumulative multiple.
SYK Dividend Profile
Yield: 1.09%. Safety: 8/8. See full history.
SYK Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
SYK Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.